Yamada Y, Inoue R, Fukao T, Kaneko H, Isogai K, Fukuda S, Shimozawa N, Suzuki Y, Kondo N, Azuma E, Sakurai M
Department of Pediatrics, Gifu University, School of Medicine, Japan.
Pediatr Hematol Oncol. 1998 Sep-Oct;15(5):425-9. doi: 10.3109/08880019809016571.
Ataxia telangiectasia (A-T) is a rare autosomal recessive disorder characterized by cerebellar ataxia, oculocutaneous telangiectasia, and variable degrees of humoral and cellular immunodeficiency. Affected individuals are known to exhibit a high incidence of lymphoma and leukemia. Because of increased chemosensitivity, the treatment of A-T patients with malignancies requires extremely careful planning and caution with respect to the use of chemotherapy. The authors report on a 12-year-old boy with A-T who developed B-cell lymphoma. He received a half-dose of the drugs administered according to the acute lymphoblastic leukemia (ALL) protocol issued by our children's cancer study group (9104 Standard Risk Protocol, Tokai Pediatric Oncology Study Group). As a result, he continues to be in complete remission and free of treatment complications 32 months after the diagnosis of B-cell lymphoma.
共济失调毛细血管扩张症（A-T）是一种罕见的常染色体隐性疾病，其特征为小脑共济失调、眼皮肤毛细血管扩张以及不同程度的体液免疫和细胞免疫缺陷。已知受影响个体患淋巴瘤和白血病的发生率很高。由于化疗敏感性增加，对患有恶性肿瘤的A-T患者进行治疗时，在使用化疗方面需要极其谨慎的规划和小心操作。作者报告了一名患有A-T的12岁男孩，他患上了B细胞淋巴瘤。他按照我们儿童癌症研究小组发布的急性淋巴细胞白血病（ALL）方案（9104标准风险方案，东海儿科肿瘤学研究小组）接受了半剂量的药物治疗。结果，在诊断出B细胞淋巴瘤32个月后，他持续处于完全缓解状态且没有治疗并发症。
